Penobscot Investment Management Company Inc. lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 32.1% during the 4th quarter, HoldingsChannel reports. The fund owned 4,740 shares of the biopharmaceutical company’s stock after selling 2,240 shares during the quarter. Penobscot Investment Management Company Inc.’s holdings in Gilead Sciences were worth $296,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of GILD. Bank of New York Mellon Corp increased its holdings in shares of Gilead Sciences by 199,789.8% during the third quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock valued at $2,420,587,000 after acquiring an additional 31,335,030 shares in the last quarter. Oregon Public Employees Retirement Fund increased its holdings in shares of Gilead Sciences by 5,733.7% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 28,988,297 shares of the biopharmaceutical company’s stock valued at $463,000 after acquiring an additional 28,491,386 shares in the last quarter. Capital Research Global Investors increased its holdings in shares of Gilead Sciences by 22.5% during the third quarter. Capital Research Global Investors now owns 69,854,968 shares of the biopharmaceutical company’s stock valued at $5,393,502,000 after acquiring an additional 12,818,301 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Gilead Sciences by 2.2% during the fourth quarter. BlackRock Inc. now owns 104,186,077 shares of the biopharmaceutical company’s stock valued at $6,516,839,000 after acquiring an additional 2,195,948 shares in the last quarter. Finally, TIAA CREF Investment Management LLC increased its holdings in shares of Gilead Sciences by 21.1% during the third quarter. TIAA CREF Investment Management LLC now owns 10,241,394 shares of the biopharmaceutical company’s stock valued at $790,738,000 after acquiring an additional 1,786,881 shares in the last quarter. Hedge funds and other institutional investors own 78.23% of the company’s stock.

Shares of NASDAQ:GILD opened at $65.63 on Friday. Gilead Sciences, Inc. has a twelve month low of $60.32 and a twelve month high of $80.90. The company has a debt-to-equity ratio of 1.19, a quick ratio of 3.29 and a current ratio of 3.38. The company has a market capitalization of $82.69 billion, a P/E ratio of 10.67, a price-to-earnings-growth ratio of 4.08 and a beta of 1.16.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $1.44 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.70 by ($0.26). Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same quarter in the prior year, the company posted $1.78 EPS. The company’s revenue for the quarter was down 2.6% on a year-over-year basis. On average, analysts forecast that Gilead Sciences, Inc. will post 6.23 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 28th. Shareholders of record on Friday, March 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.84%. The ex-dividend date of this dividend is Thursday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.57. Gilead Sciences’s dividend payout ratio is currently 37.07%.

In other Gilead Sciences news, Director Gayle E. Wilson sold 19,068 shares of the company’s stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $67.08, for a total value of $1,279,081.44. Following the sale, the director now owns 143,567 shares in the company, valued at approximately $9,630,474.36. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 1.16% of the company’s stock.

Several research firms have recently issued reports on GILD. ValuEngine upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Saturday, December 1st. BidaskClub upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Tuesday, December 4th. Citigroup reiterated a “buy” rating and issued a $100.00 price target on shares of Gilead Sciences in a report on Tuesday, February 5th. Wells Fargo & Co cut their price target on shares of Gilead Sciences from $95.00 to $89.00 and set an “outperform” rating on the stock in a report on Tuesday, February 5th. Finally, Zacks Investment Research downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, January 23rd. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Hold” and an average target price of $82.29.

TRADEMARK VIOLATION WARNING: This article was published by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/gilead-sciences-inc-gild-stake-lessened-by-penobscot-investment-management-company-inc/2895817.html.

About Gilead Sciences

Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

See Also: Are FAANG stocks a good investment?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.